CXCL8 and non-small cell lung carcinoma: Sanmamed et al. [84, 85], evaluated the relationship between changes in the serum interleukin-8 (IL-8) levels, an immunomodulating chemokine produced also by tumor cells [86], and the response to immunotherapy in melanoma and NSCLC patients.